Interview with Maureen Highkin on mass spectrometry analysis to assist discovery of sphingosine kinase inhibitors
AIdriven research projecting new drug developments, Pharmaceutical technology, Innovating medicine with advanced predictive analytics
A recent paper published by researchers at Pfizer and BIOCIUS Life Science described the mass spectrometry analysis of whole blood to facilitate the discovery of compounds that modulate sphingosine-1-phosphate signaling, which could have wider implications in assay design and utilization. In the following interview, Maureen Highkin, who led the assay development, discusses the research and implications with Cara Sutton from Future Science Group. Maureen Highkin graduated from Villanova University in Pennsylvania with a BSc in Biology. She worked for the University of Pennsylvania School of Medicine for five years studying the pathogenesis of coronaviruses, before starting her career with Monsanto...
